Last reviewed · How we verify
enoxaparin/tinzaparin/dalteparin
Low-molecular-weight heparins that inhibit blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.
Low-molecular-weight heparins that inhibit blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Venous thromboembolism prophylaxis in surgical patients, Treatment of deep vein thrombosis and pulmonary embolism, Acute coronary syndrome.
At a glance
| Generic name | enoxaparin/tinzaparin/dalteparin |
|---|---|
| Sponsor | Helsinki University Central Hospital |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Antithrombin III (indirect); Factor Xa and Factor IIa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
These are derived from unfractionated heparin through chemical or enzymatic depolymerization, resulting in molecules with a lower average molecular weight. They bind to antithrombin III and potentiate its inhibition of coagulation factors, particularly factor Xa (with greater selectivity than factor IIa compared to unfractionated heparin). This results in anticoagulant activity with more predictable pharmacokinetics and longer half-lives than unfractionated heparin.
Approved indications
- Venous thromboembolism prophylaxis in surgical patients
- Treatment of deep vein thrombosis and pulmonary embolism
- Acute coronary syndrome
- Thromboprophylaxis in medical patients with reduced mobility
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site hematoma
- Elevated transaminases
- Osteoporosis (with long-term use)
Key clinical trials
- Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management (NA)
- Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction (NA)
- REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults (PHASE3)
- A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants (PHASE2)
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (PHASE1)
- Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis (PHASE3)
- Pharmacokinetic Profiles of Subcutaneous Enoxaparin for Thromboprophylaxis in Critically Ill Patients With Renal Failure Treated or Not With Continuous Veno-veinous Hemofiltration. (NA)
- AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: